Bellerophon Therapeutics - BLPH Stock Forecast, Price & News

0 analysts have issued 1 year price targets for Bellerophon Therapeutics' stock. Their BLPH share price forecasts range from $19.00 to $19.00. On average, they anticipate the company's stock price to reach $19.00 in the next year. This suggests a possible upside of 1,832.9% from the stock's current price.
View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts.

Bellerophon Therapeutics' stock was trading at $3.10 at the beginning of the year. Since then, BLPH stock has decreased by 68.3% and is now trading at $0.9830.
View the best growth stocks for 2022 here.

Bellerophon Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 17,600 shares, a drop of 36.9% from the October 31st total of 27,900 shares. Based on an average daily volume of 14,800 shares, the days-to-cover ratio is presently 1.2 days. Currently, 0.2% of the shares of the company are short sold.
View Bellerophon Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our BLPH earnings forecast.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings results on Monday, November, 15th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.14.

Bellerophon Therapeutics shares reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Bellerophon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.62%), Renaissance Technologies LLC (2.06%) and Telemetry Investments L.L.C. (0.50%). Insiders that own company stock include New Mountain Investments Ii, L and Wassim Fares.
View institutional ownership trends.

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLPH stock can currently be purchased for approximately $0.98.

Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $9.38 million. The biotechnology company earns $-17,760,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com.